New dual CAR-T attack on tough leukemia shows early promise
NCT ID NCT07201727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. First, patients receive special immune cells (CAR-T cells) that target two markers on leukemia cells, followed by a second type of CAR-T cell. Then, they may get a stem cell transplant. The goal is to see if this approach is safe and can control the disease. Only 10 adults aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill tackle Tough-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
- New drug cocktail aims to boost remission in tough AML cases